Systematic review / meta-analysis / 2007
In large, methodologically sound trials, chondroitin showed minimal to no symptomatic benefit for knee or hip osteoarthritis.
A meta-analysis of 20 trials evaluated the effect of chondroitin compared with placebo or no treatment on pain in patients with osteoarthritis of the knee or hip. Overall trials displayed high heterogeneity (I2 = 92%), with larger benefits seen in smaller trials and those with poorer methodology. When restricted to the 3 large trials using intention-to-treat analysis (40% of patients), the effect size was -0.03 (95% CI, -0.13 to 0.07; I2 = 0%), corresponding to a 0.6 mm difference on a 10-cm visual analogue scale. The pooled relative risk for any adverse event across 12 trials was 0.99 (95% CI, 0.76 to 1.31). Limitations noted include generally low trial quality and the need to approximate effect sizes for 9 trials.
- Study type
- Meta-analysis of randomized or quasi-randomized controlled trials
- Who was studied
- 3,846 patients with osteoarthritis of the knee or hip across 20 trials
- What was measured
- Pain-related outcomes and adverse events
THE PAPER
Meta-analysis: chondroitin for osteoarthritis of the knee or hip.
Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P. Ann Intern Med, 2007.
PubMed 17438317 ↗DOI 10.7326/0003-4819-146-8-200704170-00009 ↗
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.